SphingoTec CEO to Attend ADLM 2026 Meeting
SphingoTec GmbH CEO Deborah Bergmann will attend ADLM 2026 Annual Meeting to discuss collaborations and advancements in critical care diagnostics.
Hennigsdorf, Germany – July 23, 2026 – SphingoTec GmbH announced that its Chief Executive Officer, Deborah Bergmann, will attend the ADLM 2026 Annual Meeting, taking place from July 26 to 30, 2026.
During the conference, SphingoTec plans to engage with current and prospective partners to discuss ongoing collaborations and opportunities to advance innovations in critical care diagnostics. These discussions are part of the company's strategy to expand the clinical and commercial reach of its biomarker portfolio.
"ADLM provides an important platform to connect with partners across the diagnostics ecosystem," said Deborah Bergmann, CEO of SphingoTec. "These discussions align with our commitment to translating biomarker innovation into clinically meaningful solutions for patients in critical care."
SphingoTec GmbH is a Germany-based biomarker company focused on out-licensing diagnostic solutions for acute medical conditions. The company develops its biomarkers to a commercial stage and partners with in vitro diagnostic (IVD) companies to make them available on various platforms. SphingoTec's proprietary biomarker portfolio includes Proenkephalin A 119-159 (penKid) for assessing kidney function in critical diseases and bioactive Adrenomedullin 1-52 (bio-ADM) for assessing endothelial function in conditions like sepsis.